Dipeptidyl Peptidase - 4 Inhibitors - An Overview of the Combination of These Molecules and Hypoglicemic Oral Drugs

Abstract

The purpose of the current review is to bring up to date some studies and data about the effects of hypoglycemic oral drugs in combination with DPP-4 inhibitors. As the medicine and pharmaceutical industry are revolutionary in type 2 diabetes protocols, scientists made a close research on patients that have combined metformin plus sulfonyurea and metformin plus DPP-4 inhibitors. Statistics showed that sulfonylurea compared to DPP-4 inhibitors, in combination with metformin, increased the risk of severe hypoglycemia, fatal and nonfatal cardiovascular diseases, and mortality. Another important discovery showed that the insulin associated with metformin increased the risk of all-caused mortality, compared with the DPP-4 inhibitors plus metformin.